Aim: The aim of this study was to assess the effect of Rexon-Eye therapy, based on quantum molecular resonance (QMR) technology, optical parameters, tear film stability, and patients’ subjective symptoms. Material and Methods: A total of 30 patients (20 women, mean age 64.9 years; 10 men, mean age 64.6 years) diagnosed with dry eye syndrome were included in the study. Common systemic comorbidities were recorded, most frequently arterial hypertension, hypercholesterolemia, thyroid disorders, type 2 diabetes mellitus, and hyperuricemia. Each patient underwent four treatment sessions (once weekly for 20 minutes) according to the manufacturer’s recommended protocol. Objective parameters – including objective scatter index (OSI), modulation transfer function cutoff (MTF cutoff), potential visual acuity (PVA), and vision break-up time (VBUT) – were assessed using the HD Analyzer before therapy and again 1 to 3 months after treatment completion. Subjective symptoms were evaluated using the standardized Ocular Surface Disease Index (OSDI) questionnaire. Results: No statistically significant changes were observed in OSI, MTF cutoff, or PVA. VBUT remained unchanged. By contrast, OSDI scores improved both statistically and clinically significantly. Conclusion: QMR therapy with the Rexon-Eye device led to significant improvement in subjective symptoms, while objective optical quality parameters showed no statistically significant changes. QMR therapy appears to be a safe and well-tolerated method that may expand therapeutic options in clinical practice.